# Study to Investigate Safety and Tolerability Single Ascending Doses of AZD4017

> **NCT00791752** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 40 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** AZD4017
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00791752
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** —
- **Final completion:** 2009-03
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2009-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00791752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00791752, "Study to Investigate Safety and Tolerability Single Ascending Doses of AZD4017". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00791752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*